Aura Biosciences (NASDAQ:AURA) Posts Earnings Results, Beats Estimates By $0.06 EPS

Aura Biosciences (NASDAQ:AURA – Get Rating) announced its quarterly earnings results on Wednesday. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.

Aura Biosciences Price Performance

AURA stock opened at $10.21 on Friday. Aura Biosciences has a twelve month low of $9.43 and a twelve month high of $24.83. The business has a 50 day simple moving average of $10.55 and a 200-day simple moving average of $12.30.

Analyst Ratings Changes

Separately, JMP Securities decreased their price objective on Aura Biosciences from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday.

Insider Activity

In other news, Director David Michael Johnson acquired 4,000 shares of the firm’s stock in a transaction dated Wednesday, December 28th. The stock was acquired at an average cost of $9.75 per share, with a total value of $39,000.00. Following the completion of the acquisition, the director now owns 17,000 shares of the company’s stock, valued at $165,750. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Several large investors have recently modified their holdings of AURA. Price T Rowe Associates Inc. MD purchased a new stake in shares of Aura Biosciences during the fourth quarter worth approximately $7,762,000. Nantahala Capital Management LLC raised its stake in shares of Aura Biosciences by 204.6% during the first quarter. Nantahala Capital Management LLC now owns 301,990 shares of the company’s stock worth $6,644,000 after purchasing an additional 202,844 shares during the last quarter. State Street Corp raised its stake in shares of Aura Biosciences by 202.1% during the second quarter. State Street Corp now owns 256,746 shares of the company’s stock worth $3,638,000 after purchasing an additional 171,764 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Aura Biosciences by 39.2% during the third quarter. Vanguard Group Inc. now owns 605,884 shares of the company’s stock worth $10,978,000 after purchasing an additional 170,709 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of Aura Biosciences by 14.3% during the third quarter. BlackRock Inc. now owns 1,013,455 shares of the company’s stock worth $18,363,000 after purchasing an additional 126,732 shares during the last quarter. Hedge funds and other institutional investors own 55.63% of the company’s stock.

About Aura Biosciences

(Get Rating)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.